William P Scully bought $2.7M of Prothena (PRTA)
Executed Dec 18 2024, disclosed May 2 2025, 135 days later, against a two-business-day limit.
Over the 21 trading sessions from the disclosed entry session (May 2 2025), the stock returned -46.7% (delay-adjusted); from the execution session (Dec 18 2024), +0.6%. Derived: entry at the session's open, exit at the close 20 sessions later.
William P Scully (10% owner) filed 9 Form 4 reports in the trailing twelve months (9 purchases, 0 sales), most often in Prothena Corporation plc (PRTA). Across 7 priced purchase filings, the average 21-session return was +4.5% from execution and +1.8% from disclosure (delay-adjusted; derived). The largest single filing was $1.0M of PRTA (125,000 sh × $8.17, as filed), executed Jun 11.
Healthcare · Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat dis…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→100,000 sh × $8.43
Exec Sep 18
Filed Sep 21 · 4:23 PM ET PRTAPURCHASE Prothena Corporation plc $256K
27,000 sh × $9.47
Exec Sep 2
Filed Sep 3 · 6:23 PM ET PRTAPURCHASE Prothena Corporation plc $439K
50,000 sh × $8.79
Exec Aug 20
Filed Aug 21 · 2:32 PM ET PRTAPURCHASE Prothena Corporation plc $293K
34,000 sh × $8.62
Exec Aug 7
Filed Aug 10 · 3:24 PM ET PRTAPURCHASE Prothena Corporation plc $158K
20,000 sh × $7.90
Exec Jun 16
Filed Jun 18 · 11:38 AM ET PRTAPURCHASE Prothena Corporation plc $1.0M
125,000 sh × $8.17
Exec Jun 11
Filed Jun 12 · 5:59 PM ET PRTAPURCHASE Prothena Corporation plc $465K
50,000 sh × $9.31
Exec Jun 4
Filed Jun 5 · 1:46 PM ET PRTAPURCHASE Prothena Corporation plc $471K
50,000 sh × $9.43
Exec Jun 2
Filed Jun 3 · 12:41 PM ET